Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Moderna | Vintage Vibes

Short Squeeze Alert—Moderna Stock Surges on New Strategy

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.

MarketBeat

MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.

Barchart

Stocks Struggle After OpenAI IPO Blow: Stock Market Today

Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

US stocks: US market ends lower as tech stocks weigh on sentiment

Wall Street ended lower on Friday, with AI chip stocks experiencing a significant downturn while Moderna and other healthcare companies surged. Investors are weighing the long-term potential of AI against concerns about the substantial investment required for data centers. Inflationary pressures, fueled by energy prices and chip costs, remain a…

The Economic Times

FDA Panel Backs Moderna's First mRNA Flu Shot — What It Could Mean for Your Fall Vaccine

FDA advisers unanimously backed Moderna's mRNA flu vaccine mFlusiva on June 18. Here's what the 9-0 vote means for fall 2026 vaccination and who it would cover.

Medical Daily

FDA panel backs first-of-its-kind flu vaccine using mRNA technology

A new kind of flu vaccine is moving a step closer to the U.S. market

AAP

FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Intense Scrutiny

FDA VRBPAC votes June 18 on Moderna's MFLUSIVA — the first mRNA flu vaccine. Phase 3 showed 26.6% RVE vs. standard dose; 47.9% vs. healthcare outcomes. PDUFA August 5, 2026.

Medical Daily

Read news from The Economist, FT, and more,
with one subscription

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

U.S. health advisers are debating a new kind of flu vaccine

AAP

New mRNA flu vaccine faces scrutiny ahead of key FDA decision

U.S. health advisers are debating a new kind of flu vaccine

The Independent UK

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.

Euronews

3 new Ebola vaccines are being fast-tracked amid the current outbreak — when could they be ready?

The Bundibugyo virus driving the current Ebola outbreak has no approved vaccine, but researchers are leveraging decades of vaccine innovation in an effort to change that.

LiveScience

Oxford University and Moderna to trial pioneering cancer vaccine

IN FULL

The Independent UK

Oxford University and Moderna launch trials of vaccine that could prevent cancer

The jab targets patients with Lynch syndrome, who are at high risk of colorectal and ovarian cancer

The Independent UK

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access…

The Economic Times

Moderna and other groups get $60 million to develop Ebola vaccine

CEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will support Moderna, the University of Oxford, and the International AIDS Vaccine Initiative. The goal is to have trial-ready vaccines within months.

MarketBeat

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

MarketBeat

Immunovant Q4 Earnings Call Highlights

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

Staged claims and Israeli hoaxes: Debunking viral conspiracy theories about hantavirus

Misinformation about hantavirus has run rampant on social media, with online users reviving viral COVID-19 theories to spread fake news about the outbreak.

International Business Times UK

Is There A Cure For Hantavirus Infection? 'Breathed In' Virus Kills 38% Of Patients, Scientists Race For Vaccine

A deadly cruise ship outbreak of the Andes strain has revived global interest in a long‑delayed hantavirus cure, as scientists warn that early hospital care can make the difference between survival and a 38% fatality risk.

Barchart

Moderna Stock Is Surging on Hantavirus Threats. Its Chart Offers a Harsh Dose of Reality.

A localized outbreak, even a fatal one, is unlikely to spark the multibillion-dollar revenue catalyst that Moderna needs.

Barchart

Is Wall Street Bullish or Bearish on Moderna Stock?

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Evening Standard

Major trial for human bird flu vaccine launches

Around 4,000 people will be recruited for the study, the majority of which will be in the UK.

The Independent UK

Bird flu vaccine trial begins to fight ‘real possibility’ of virus threat for humans

The vaccine will utilise mRNA technology similar to that employed in Covid-19 jabs

Barchart

Moderna's Quarterly Earnings Preview: What You Need to Know

Moderna is expected to announce its fiscal first-quarter earnings next month, and analysts project a high single-digit decline in losses.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.